Bristol

Bristol Myers Squibb Advances Hodgkin Lymphoma Care Expanded Opdivo Approvals

Bristol Myers Squibb gains U.S. Food and Drug Administration and European Medicines Agency approvals, expanding Opdivo use in Hodgkin lymphoma Bristol Myers Squibb has announced significant regulatory milestones that mark a major advancement in the treatment landscape for classical Hodgkin…

Read MoreBristol Myers Squibb Advances Hodgkin Lymphoma Care Expanded Opdivo Approvals
Curi

Curi Bio & Battelle Partner to Advance Neuromuscular Drug Testing

Strategic Collaboration to Accelerate Human-Relevant Neuromuscular Testing Curi Bio and Battelle have announced a strategic collaboration aimed at transforming the field of neuromuscular pharmacology through the accelerated adoption of New Approach Methods (NAMs). This partnership represents a significant step forward…

Read MoreCuri Bio & Battelle Partner to Advance Neuromuscular Drug Testing
Aptars

Aptar’s Unidose Nasal Powder System Featured in Phase II Study of ENA’s INNA-051 Nasal Spray

Aptar’s Introduction to INNA-051 Investigational Nasal Spray AptarGroup a global leader in drug delivery, dosing, and protection technologies, has announced the use of its Unidose (UDS) Powder Nasal Spray System in a Phase II clinical study being conducted by ENA…

Read MoreAptar’s Unidose Nasal Powder System Featured in Phase II Study of ENA’s INNA-051 Nasal Spray
Fulgent

Fulgent Genetics completes acquisition of Bako Diagnostics and StrataDx

Fulgent Genetics finalizes $56.9 million deal to expand pathology and dermatopathology capabilities with Bako Diagnostics and StrataDx Fulgent Genetics, Inc., a technology-driven company known for its strong laboratory services platform and growing therapeutic development efforts, has officially completed its previously…

Read MoreFulgent Genetics completes acquisition of Bako Diagnostics and StrataDx
WuXi Biologics

WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership

WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Advancements in Bioprocessing, Manufacturing Quality, and Digital Innovation WuXi Biologics a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual…

Read MoreWuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership